跳至主要内容
临床试验/IRCT20120703010178N26
IRCT20120703010178N26尚未招募3 期

The impact of saffron total glycoside tablets on Doxorubicin-induced cardiotoxicity in patients with breast cancer: Randomized clinical trial

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 188 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
188

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
Female

入选标准

  • Female patients aged 18 to 70 years
  • Patients with histologically or cytologically proven primary breast cancer
  • Receiving chemotherapy with doxorubicin, without prior bilateral/unilateral thoracic radiotherapy
  • Karnofsky score more than 60
  • Life expectancy more than 6 months

排除标准

  • Patients diagnosed with cardiomyopathy
  • Patients receiving vitamin K antagonists or DOACs
  • Patients with chronic kidney disease with eGFR < 30 ml/min/1.73 m2
  • Patients with serum potassium above 5.5 mmol/L
  • Patients with severe liver failure (Child-Pough C)
  • Patients who have previously received anthracycline
  • Patients who are currently pregnant or breastfeeding
  • Patients participating in other clinical trials

研究者

相似试验